3/7/2024 | BKEMHY | Fitch revises Teva outlook to positive
|
5/31/2023 | BKCVEMHY | S&P turns Teva outlook to stable
|
3/13/2023 | EMHYLM | Teva gives results, ups caps in offer for $2.5 billion of notes
|
3/6/2023 | BKCVEMHY | S&P assigns BB- to Teva notes
|
3/1/2023 | HY | Market Commentary: Junk primary prices $3.65 billion; Triumph flat in secondary; Adient stumbles, recovers
|
3/1/2023 | EMGNHY | New Issue: Teva prices upsized $2.49 billion equivalent sustainability notes in four tranches
|
3/1/2023 | BKCVEMGNHY | Fitch assigns BB- to Teva notes
|
3/1/2023 | EMGNHY | Teva upsizes to $2.49 billion, hones talk on four-part notes offering; pricing Wednesday
|
2/28/2023 | HY | Market Commentary: Junk: $2.2 billion of new paper; Consolidated Communications falls; Ranger Oil spikes
|
2/28/2023 | EMGNHY | Moody's assigns Ba2 to Teva notes
|
2/28/2023 | EMGNHY | Teva sets talk in $2.06 billion four-part sustainability-linked notes offering; pricing Wednesday
|
2/27/2023 | BKCVDDEMIGPV | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
2/27/2023 | HY | Market Commentary: Triumph, Teva on deck; Tegna tanks on FCC acquisition opposition; TransDigm, Uniti improve
|
2/27/2023 | EMHYLM | Teva starts tender offer for $2.25 billion of notes due 2023 to 2026
|
2/27/2023 | EMGNHY | Teva starts roadshow for $2.06 billion four-part offering of sustainability-linked notes
|
2/24/2023 | HY | Market Commentary: Junk moves lower on inflation data; TransDigm lower; Medical Properties pressured
|
2/24/2023 | EMHY | Israel’s Teva sets non-deal roadshow via Citigroup and Goldman Sachs in week ahead
|
10/20/2022 | SP | New Issue: UBS prices $503,000 trigger phoenix autocallables linked to Teva
|
10/20/2022 | SP | New Issue: UBS prices $1.28 million trigger phoenix autocallables linked to Teva
|
10/11/2022 | SP | New Issue: UBS prices $503,000 trigger phoenix autocallables linked to Teva
|
10/11/2022 | SP | New Issue: UBS prices $1.28 million trigger phoenix autocallables linked to Teva
|
9/23/2022 | SP | New Issue: UBS prices $2.67 million trigger phoenix autocallables linked to Teva
|
9/1/2022 | SP | New Issue: UBS prices $1.23 million trigger phoenix autocallables linked to Teva
|
7/29/2022 | BKCVEMGNHY | S&P lifts Teva outlook to positive
|
7/27/2022 | BKCVDDEMIGPV | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
7/27/2022 | HY | Market Commentary: Pharma bonds mixed following Teva opioid settlement; Endo mostly lower; Bausch improves
|
7/27/2022 | DD | Market Commentary: Pharma bonds mixed following Teva opioid settlement; Endo mostly lower; Bausch improves
|
7/27/2022 | HY | Market Commentary: Avient prices; secondary surges post-Fed; cross-over credits in demand; Teva gains on settlement
|
7/6/2022 | SP | New Issue: UBS prices $1.32 million trigger phoenix autocallables linked to Teva Pharmaceutical
|
7/6/2022 | SP | New Issue: UBS prices $308,000 trigger phoenix autocallables linked to Teva Pharmaceutical
|
5/24/2022 | SP | New Issue: UBS prices $1.18 million trigger phoenix autocallables linked to Teva
|
4/21/2022 | SP | New Issue: UBS prices $120,000 trigger phoenix autocallables linked to Teva
|
4/12/2022 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva
|
3/18/2022 | SP | New Issue: UBS prices $2.89 million trigger phoenix autocallables linked to Teva
|
2/18/2022 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva
|
12/15/2021 | BKCVEMGNHY | Moody's turns Teva outlook to stable
|
12/7/2021 | SP | New Issue: UBS prices $500,000 contingent absolute return autocallables linked to Teva
|
12/7/2021 | SP | New Issue: UBS prices $530,000 contingent absolute return autocallables linked to Teva
|
12/7/2021 | SP | New Issue: UBS prices $150,000 contingent absolute return autocallables linked to Teva
|
12/6/2021 | BKCVEMGNHY | Fitch revises Teva view to stable
|
11/10/2021 | EMHYLM | Teva gives early tender results for six series, lifts cap to $4 billion
|
11/5/2021 | EM | Market Commentary: Emerging markets: Teva prices upsized $5 billion equivalent notes: NPC Ukrenergo debuts
|
11/5/2021 | HY | Market Commentary: Morning Commentary: United Site 8% notes 103 bid; PIK toggle dividend deals return
|
11/4/2021 | BKCVDDEMIGPV | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
11/4/2021 | HY | Market Commentary: DCP Midstream, Asbury Automotive price; Teva active; Continental gains; CommScope sinks
|
11/3/2021 | BKCVDDEMIGPV | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
11/3/2021 | HY | Market Commentary: Junk secondary unmoved by Fed tapering statement; Teva flat; Jane Street on a 101-handle
|
11/3/2021 | SP | New Issue: UBS prices $1.57 million contingent absolute return autocallables linked to Teva
|
11/2/2021 | HY | Market Commentary: Jane Street, Teva price HY bonds; Mr. Cooper improves; Navient flat; Molina struggles
|
11/2/2021 | EMGNHY | New Issue: Teva Pharmaceutical prices upsized $5 billion equivalent sustainability-linked notes
|
11/1/2021 | BKCVDDEMIGPV | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
11/1/2021 | HY | Market Commentary: Mr. Cooper, Navient price; loanDepot gains on earnings beat; PG&E active
|
11/1/2021 | EMGNHY | Teva sets price talk in $4 billion equivalent four-part sustainability notes offer, pricing Tuesday
|
10/29/2021 | EM | Market Commentary: Emerging Markets: Peru brings sustainable bonds; Teva on tap; Modern Land skips payment
|
10/27/2021 | HY | Market Commentary: CA Magnum/Hexaware prices; Roblox struggles in junkland; Gray Television on a 101-handle
|
10/27/2021 | EMGNHY | Junk investors dig in on Teva’s $4 billion four-part offering of sustainability-linked notes
|
10/27/2021 | EMHYLM | Teva Pharmaceutical commences capped cash tender offer for six series of notes
|
10/27/2021 | EMHY | S&P assigns Teva notes BB-
|
10/27/2021 | EMHYLM | Teva Pharmaceutical begins cash tender offer for six series of notes
|
10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes; pricing expected Tuesday
|
10/27/2021 | EMGNHY | Teva markets $4 billion equivalent dollar, euro sustainability notes
|
10/27/2021 | EMHY | Moody's rates Teva notes Ba2
|
6/26/2021 | SP | New Issue: UBS prices $157,000 trigger phoenix autocallables linked to Teva
|
6/26/2021 | SP | New Issue: UBS prices $1.63 million trigger phoenix autocallables linked to Teva
|
4/27/2021 | SP | New Issue: UBS prices $100,000 trigger autocallables linked to Teva
|
3/9/2021 | SP | New Issue: UBS prices $2.1 million trigger phoenix autocallables linked to Teva Pharmaceutical
|
2/17/2021 | SPSW | Structured products issuance at $1.29 billion for month as market rallies, volatility high
|
2/11/2021 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva
|
12/4/2020 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva Pharmaceutical
|
12/3/2020 | SP | New Issue: UBS prices $2.02 million trigger phoenix autocallables linked to Teva
|
9/4/2020 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva
|
9/3/2020 | CV | S&P trims Teva
|
9/3/2020 | BKCVEMHY | S&P trims Teva
|
8/26/2020 | SP | New Issue: UBS prices $1.6 million trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
6/18/2020 | SP | New Issue: UBS prices $545,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
6/18/2020 | SP | New Issue: UBS prices $2.38 million trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
3/4/2020 | SP | New Issue: Morgan Stanley prices $1 million 8.76% fixed-coupon autocallables tied to Teva
|
2/12/2020 | DD | Market Commentary: Whiting lower after financial adviser report; Endo, Mallinckrodt lifted in pharma space
|
12/16/2019 | SP | New Issue: UBS prices $1.54 million trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
11/25/2019 | DDEMHYLM | Teva gives early results for tenders for 2.2%, 3.65% notes due 2021
|
11/21/2019 | EMHYLM | Teva Pharmaceutical to redeem €650 million of 3/8% notes
|
11/19/2019 | DD | Market Commentary: PG&E lower amid state settlement news; California Resources drops as fracking halted
|
11/19/2019 | EMHY | New Issue: Teva Pharmaceutical prices $1 billion 7 1/8% notes and €1 billion 6% notes at par
|
11/19/2019 | EMHY | Teva Pharmaceutical upsizes bond tranches, tightens talk amid huge demand; pricing Tuesday
|
11/19/2019 | EMHY | Teva Pharmaceutical ups bond tranches to $1 billion and €1 billion, tightens talk; pricing Tuesday
|
11/18/2019 | BKCVDDEMIGPV | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands trades up
|
11/18/2019 | HY | Market Commentary: iHeart, Boyd, Mattel, MSCI add-on price; Prestige Brands, Univar, Maxar trade up; Intelsat sinks
|
11/18/2019 | EMHY | Teva sets tranches, talk for upsized $2 billion equivalent long five-year dual-currency notes
|
11/15/2019 | HY | Market Commentary: Univar, Maxar, Prestige price; Centene plans $7 billion; Hertz, Restaurant Brands up
|
11/15/2019 | DD | Market Commentary: Intelsat notes improve after filing auction plan; J.C. Penney higher on mixed earnings
|
11/14/2019 | BKCVEM | Moody’s rates Teva notes Ba2
|
11/13/2019 | HY | Market Commentary: Wesco clears the market; Targa prices; Sealed Air, goeasy lag; Outfront, Scientific Games trade up
|
11/13/2019 | BKCVEM | S&P rates Teva notes BB
|
11/13/2019 | EMHY | Teva Pharmaceutical sets initial price talk in $1.5 billion dollar, euro notes offering
|
11/8/2019 | HY | Market Commentary: Teva rises after starting tender offers; Revlon notes head lower following earnings
|
11/8/2019 | DD | Market Commentary: Teva rises after starting tender offers; Revlon notes head lower following earnings
|
11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
11/8/2019 | BKCVDDEMIGPV | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
11/8/2019 | HY | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
11/8/2019 | HY | Market Commentary: Wesco PattonAir downsizes; Albertsons improves; LPL up; Teva active; Wildhorse rebounds
|
11/8/2019 | DDEMHYLM | Teva tenders for 2.2%, 3.65% notes, will spend up to $1.5 billion
|
11/8/2019 | EMHY | Teva Pharmaceutical sets roadshow for $1.5 billion two-part bullet deal in dollars and euros
|
11/7/2019 | HY | Market Commentary: Party City dives after earnings miss; Teva trades mixed on guidance, CFO appointment
|
11/7/2019 | DD | Market Commentary: Party City dives after earnings miss; Teva trades mixed on guidance, CFO appointment
|
11/5/2019 | SP | New Issue: UBS prices $99,994 21.17% trigger yield optimization notes linked to Teva Pharmaceutical
|
10/28/2019 | DD | Market Commentary: PG&E dives as blackouts, wildfires persist; McDermott declines after ratings downgrade
|
10/25/2019 | DD | Market Commentary: PG&E notes drop amid wildfire worries; WeWork trades higher as rescue funding detailed
|
10/25/2019 | SP | New Issue: UBS prices $749,993 16.54% trigger yield optimization notes linked to Teva Pharmaceutical
|
10/24/2019 | HY | Market Commentary: PG&E notes trade lower amid more power blackouts; Teva paper declines in pharma space
|
10/24/2019 | DD | Market Commentary: PG&E notes trade lower amid more power blackouts; Teva paper declines in pharma space
|
10/24/2019 | BKCVEM | S&P places Teva ratings on CreditWatch negative
|
10/23/2019 | DD | Market Commentary: WeWork lower as layoffs expected; Chemours down after liability talk
|
10/22/2019 | HY | Market Commentary: Netflix, Liberty Cablevision price; euro junk market sees tightest print ever; newer notes rise
|
10/22/2019 | DD | Market Commentary: WeWork notes weaken as financial rescue deal reached; Rite Aid active amid upgrade
|
10/21/2019 | BKCVDDEMIGPV | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
10/21/2019 | HY | Market Commentary: United Rentals, KB Home price; newer notes trade; Teva lifted; Coty falls; WeWork higher
|
10/21/2019 | HY | Market Commentary: McDermott notes drop on rescue financing; Teva lifted after opioid settlement news
|
10/21/2019 | DD | Market Commentary: McDermott notes drop on rescue financing; Teva lifted after opioid settlement news
|
10/21/2019 | CV | Market Commentary: Snap convertibles little moved as shares jump; Workday notes active near recent lows
|
10/18/2019 | BKCVDDEMIGPV | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
10/18/2019 | HY | Market Commentary: Neptune Energy adds; Evoca prices; Thursday issuance higher; Teva up; WeWork better
|
10/18/2019 | HY | Market Commentary: L Brands bonds active after analyst comments; Teva Pharmaceutical notes edge higher
|
10/18/2019 | DD | Market Commentary: L Brands bonds active after analyst comments; Teva Pharmaceutical notes edge higher
|
10/17/2019 | HY | Market Commentary: Europe primary active; Charter, Speedway, Merlin trading up; Netflix moves higher
|
10/17/2019 | HY | Market Commentary: Teva active as settlement reportedly nears; Gulfport Energy rises on production news
|
10/17/2019 | DD | Market Commentary: Teva active as settlement reportedly nears; Gulfport Energy rises on production news
|
10/16/2019 | BKCVDDEMIGPV | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names up; Sprint, T-Mobile higher
|
10/16/2019 | HY | Market Commentary: Merlin, Speedway price; new Charter notes rise; pharma names lifted; Sprint, T-Mobile higher
|
10/16/2019 | HY | Market Commentary: Pharma names improve on settlement news; Rite Aid declines after ratings downgrade
|
10/16/2019 | DD | Market Commentary: Pharma names improve on settlement news; Rite Aid declines after ratings downgrade
|
10/15/2019 | DD | Market Commentary: PG&E lower as company enters debt commitments; Whiting down after acquisition news
|
10/10/2019 | DD | Market Commentary: PG&E notes down after restructuring news; U.S. Steel mixed on preliminary Q3 results
|
10/9/2019 | DD | Market Commentary: U.S. Steel notes weaken after CFO departure; PG&E lower amid exclusivity termination
|
10/8/2019 | DD | Market Commentary: Frontier Communications notes head lower; PG&E paper improves amid stakeholder dispute
|
10/7/2019 | DD | Market Commentary: PG&E lower amid victim payout dispute; Bristow notes up as bankruptcy exit expected
|
10/4/2019 | DD | Market Commentary: EP Energy notes better after bankruptcy filing; PG&E declines amid financing update
|
10/3/2019 | DD | Market Commentary: Bed Bath & Beyond trades mixed after earnings; PG&E better amid restructuring spat
|
10/2/2019 | DD | Market Commentary: PG&E declines as stakeholders clash; U.S. Steel notes weaken after revised outlook
|
9/26/2019 | DD | Market Commentary: Rite Aid better on earnings report; Halcon Resources lower after bankruptcy exit news
|
9/25/2019 | DD | Market Commentary: Dean Foods lower after CFO departure; Diamond Offshore down amid ratings downgrade
|
9/24/2019 | DD | Market Commentary: McDermott International notes decline in energy space; PG&E higher amid creditor spat
|
9/23/2019 | DD | Market Commentary: PG&E lower in reorganization dispute; McDermott notes decline amid ratings downgrade
|
9/20/2019 | HY | Market Commentary: McDermott better on asset sale talk; PG&E paper rises amid dueling reorganization plans
|
9/20/2019 | DD | Market Commentary: McDermott better on asset sale talk; PG&E paper rises amid dueling reorganization plans
|
9/19/2019 | HY | Market Commentary: Chesapeake Energy notes lower after senior note swap; Teva weakens in pharma space
|
9/19/2019 | DD | Market Commentary: Chesapeake Energy notes lower after senior note swap; Teva weakens in pharma space
|
9/16/2019 | DD | Market Commentary: Oil names lifted as futures skyrocket; Frontier Communications mixed on interest payment
|
9/12/2019 | DD | Market Commentary: Alta Mesa drops on bankruptcy; Mallinckrodt notes gain after second rating downgrade
|
9/11/2019 | DD | Market Commentary: Mallinckrodt active in pharma space; EP Energy notes improve after skipped payment
|
9/9/2019 | DD | Market Commentary: Mallinckrodt lower after ratings downgrade; oil names see boost from Saudi comments
|
9/6/2019 | DD | Market Commentary: Mallinckrodt mixed on settlement news; PG&E better in run-up to restructuring plan
|
9/5/2019 | DD | Market Commentary: Mallinckrodt sinks on restructuring talk; Bed Bath better after announcing revamp plan
|
9/4/2019 | DD | Market Commentary: U.S. Steel mixed after ratings downgrade; PG&E notes lower on bankruptcy development
|
9/3/2019 | DD | Market Commentary: Intelsat lower on C-band group fracture; Navios Maritime notes drop after division sale
|
8/30/2019 | DD | Market Commentary: Mallinckrodt continues slide in pharma space; J.C. Penney up amid executive stock buys
|
8/29/2019 | DD | Market Commentary: Mallinckrodt bonds drop after drawing down revolver; Whiting active on tender offer
|
8/28/2019 | BKCVDDEMIGPV | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
8/28/2019 | HY | Market Commentary: Pharma space under pressure; Rackspace higher; Tallgrass negative; oil names rise
|
8/28/2019 | HY | Market Commentary: Pharma names lower on more settlement news; Rackspace improves after conference call
|
8/28/2019 | DD | Market Commentary: Pharma names lower on more settlement news; Rackspace improves after conference call
|
8/27/2019 | BKCVDDEMIGPV | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
8/27/2019 | HY | Market Commentary: Pharma names see negativity; Range Resources varies; GTT declines
|
8/27/2019 | HY | Market Commentary: Endo, Teva drop post-settlement news; Range Resources active, flat after downgrade
|
8/27/2019 | DD | Market Commentary: Endo, Teva drop post-settlement news; Range Resources active, flat after downgrade
|
8/23/2019 | DD | Market Commentary: L Brands bonds lower after analyst downgrade; Endo paper declines in pharma space
|
8/22/2019 | HY | Market Commentary: L Brands bonds active, mixed after earnings report; CBL eyed after delisting notice
|
8/22/2019 | DD | Market Commentary: L Brands bonds active, mixed after earnings report; CBL eyed after delisting notice
|
8/21/2019 | HY | Market Commentary: L Brands lower on earnings anticipation; Endo International notes continue to rise
|
8/21/2019 | DD | Market Commentary: L Brands lower on earnings anticipation; Endo International notes continue to rise
|
8/20/2019 | HY | Market Commentary: PG&E continues to decline; Endo gains after settling suit; Tenet varies
|
8/20/2019 | HY | Market Commentary: Endo International gains after lawsuit settlement news; PG&E weakens in utilities space
|
8/20/2019 | DD | Market Commentary: Endo International gains after lawsuit settlement news; PG&E weakens in utilities space
|
8/19/2019 | DD | Market Commentary: PG&E lower on wildfire claim ruling; Sanchez Energy notes gain after financing news
|
8/16/2019 | DD | Market Commentary: Exela Technologies lower after ratings downgrade; Revlon notes weaken in retail sector
|
8/15/2019 | HY | Market Commentary: J.C. Penney better after earnings report; PG&E drops on negative report
|
8/15/2019 | DD | Market Commentary: J.C. Penney better after earnings report; PG&E drops on negative report
|
8/14/2019 | HY | Market Commentary: Teva drops on negative outlook, government pressure; Dean lower on agency downgrade
|
8/14/2019 | DD | Market Commentary: Teva drops on negative outlook, government pressure; Dean lower on agency downgrade
|
8/14/2019 | BKCVEM | Moody’s revises Teva view to negative
|
8/13/2019 | HY | Market Commentary: GTT better on ownership disclosure; Mattel gains on global trade news
|
8/13/2019 | DD | Market Commentary: GTT better on ownership disclosure; Mattel gains on global trade news
|
8/13/2019 | BKCVDDEMIGPV | Market Commentary: Post Labor Day pipeline eyed; Tenet bounces off lows; Teva drops; Goodyear Tire rises
|
8/13/2019 | HY | Market Commentary: Post Labor Day pipeline eyed; Tenet Healthcare bounces off lows; Teva drops; Goodyear Tire rises
|
8/9/2019 | HY | Market Commentary: Exela crashes on disappointing earnings; Mallinckrodt lower amid lawsuit news
|
8/9/2019 | DD | Market Commentary: Exela crashes on disappointing earnings; Mallinckrodt lower amid lawsuit news
|
8/8/2019 | HY | Market Commentary: GTT, Rayonier dive on quarterly misses; Teva rises in pharma space
|
8/8/2019 | DD | Market Commentary: GTT, Rayonier dive on quarterly misses; Teva rises in pharma space
|
8/7/2019 | HY | Market Commentary: Frontier, Teva down despite earnings beat; Denbury rises after quarterly numbers
|
8/7/2019 | DD | Market Commentary: Frontier, Teva down despite earnings beat; Denbury rises after quarterly numbers
|
8/6/2019 | HY | Market Commentary: Endo rises despite negative earnings, sector negativity; Adient gains on quarterly report
|
8/6/2019 | DD | Market Commentary: Endo rises despite negative earnings, sector negativity; Adient gains on quarterly report
|
8/5/2019 | DD | Market Commentary: Diamond Offshore dives after earnings miss; Chemours down in chemicals space
|
8/5/2019 | HY | Market Commentary: Diamond Offshore dives after earnings miss; Chemours down in chemicals space
|
8/2/2019 | HY | Market Commentary: California Resources, Valaris fall post-earnings; Chemours off in chemical space
|
8/2/2019 | DD | Market Commentary: California Resources, Valaris fall post-earnings; Chemours off in chemical space
|
7/31/2019 | HY | Market Commentary: Range Resources better post earnings; Frontier active, diverge in telecom space
|
7/31/2019 | DD | Market Commentary: Range Resources better post earnings; Frontier active, diverge in telecom space
|
7/30/2019 | HY | Market Commentary: McDermott slips after earnings, guidance; Intelsat better on mixed earnings
|
7/30/2019 | DD | Market Commentary: McDermott slips after earnings, guidance; Intelsat better on mixed earnings
|
7/29/2019 | HY | Market Commentary: Teva higher as settlement reached; LSC Communications declines on downgrade
|
7/29/2019 | DD | Market Commentary: Teva higher as settlement reached; LSC Communications declines on downgrade
|
7/26/2019 | DD | Market Commentary: Mattel better after earnings report; DISH higher as Sprint, T-Mobile merger approved
|
7/25/2019 | HY | Market Commentary: Diebold Nixdorf up after earnings, maturities news; PG&E lower as wildfire fund detailed
|
7/25/2019 | DD | Market Commentary: Diebold Nixdorf paper up after earnings, maturities news; PG&E lower as wildfire fund detailed
|
7/24/2019 | DD | Market Commentary: Superior Energy notes active after earnings miss; PG&E mixed amid creditor dispute
|
7/23/2019 | HY | Market Commentary: Bed Bath & Beyond mixed on layoff news; LSC notes tank after merger cancelled
|
7/23/2019 | DD | Market Commentary: Bed Bath & Beyond mixed on layoff news; LSC notes tank after merger cancelled
|
7/23/2019 | BKCVDDEMIGPV | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters
|
7/23/2019 | HY | Market Commentary: JBS USA, Five Point add-on price; Teva in focus; LSC Communications craters; Realogy rebounds
|
7/22/2019 | HY | Market Commentary: Mallinckrodt dips on negative attention; Halcon Resources lower on restructuring chatter
|
7/22/2019 | DD | Market Commentary: Mallinckrodt dips on negative attention; Halcon lower on restructuring chatter; U.S. Steel up
|
7/19/2019 | HY | Market Commentary: Mallinckrodt’s woes continue; Teva drops; J.C. Penney explores options
|
7/19/2019 | DD | Market Commentary: Mallinckrodt’s woes continue; Teva drops; J.C. Penney explores options
|
7/15/2019 | HY | Market Commentary: Endo, Teva under pressure; Intelsat drops; Cincinnati Bell recoups losses
|
7/15/2019 | DD | Market Commentary: Endo, Teva under pressure; Intelsat drops; Cincinnati Bell recoups losses
|
7/15/2019 | HY | Market Commentary: Trivium, Trident TPI on tap; E.W. Scripps, Masonite improve; Carrizo Oil & Gas up on buyout
|
7/11/2019 | HY | Market Commentary: Bed Bath & Beyond down after earnings; PG&E better on fund approval
|
7/11/2019 | DD | Market Commentary: Bed Bath & Beyond down after earnings; PG&E better on fund approval
|
7/5/2019 | BKCVDDEMIGPV | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
7/5/2019 | HY | Market Commentary: Trading light; Altice USA backs off gains; Teva active but flat; funds add $800 million
|
7/5/2019 | HY | Market Commentary: Weatherford better as DIP financing approved; Teva down in pharma space
|
7/5/2019 | DD | Market Commentary: Weatherford better as DIP financing approved; Teva down in pharma space
|
7/1/2019 | HY | Market Commentary: Weatherford drops on bankruptcy filing; Endo lower after ratings downgrade
|
7/1/2019 | DD | Market Commentary: Weatherford drops on bankruptcy filing; Endo lower after ratings downgrade
|
6/28/2019 | HY | Market Commentary: Digicel drops after earnings miss; PetSmart better as debt upgraded; Rite Aid better
|
6/28/2019 | DD | Market Commentary: Digicel drops after earnings miss; PetSmart better as debt upgraded; Rite Aid better
|
6/26/2019 | HY | Market Commentary: Ensco Rowan jumps; energy trends higher; Frontier mixed amid ratings downgrade
|
6/26/2019 | DD | Market Commentary: Ensco Rowan jumps; energy trends higher; Frontier mixed amid ratings downgrade
|
6/26/2019 | SP | New Issue: UBS sells $500,000 trigger phoenix autocallables on Teva Pharmaceutical
|
6/25/2019 | HY | Market Commentary: PG&E lower as creditors propose restructure plan; GTT slides on analyst downgrade
|
6/25/2019 | DD | Market Commentary: PG&E lower as creditors propose restructure plan; GTT slides on analyst downgrade
|
6/24/2019 | HY | Market Commentary: PG&E rises after restructure plan floated; Teva mixed as settlement approved
|
6/24/2019 | DD | Market Commentary: PG&E rises after restructure plan floated; Teva mixed as settlement approved
|
6/18/2019 | HY | Market Commentary: Windstream higher as Uniti lease in question; PetSmart declines in retail
|
6/18/2019 | DD | Market Commentary: Windstream higher as Uniti lease in question; PetSmart declines in retail
|
6/17/2019 | HY | Market Commentary: Denbury mixed as early exchange results come in; Frontier lower in telecom space
|
6/17/2019 | DD | Market Commentary: Denbury mixed as early exchange results come in; Frontier lower in telecom space
|
6/14/2019 | HY | Market Commentary: PetSmart better on Chewy IPO; Frontier lower amid restructure talk
|
6/14/2019 | DD | Market Commentary: PetSmart better on Chewy IPO; Frontier lower amid restructure talk
|
6/13/2019 | HY | Market Commentary: Hertz spikes on rights offering; Frontier mixed in telecom space
|
6/13/2019 | DD | Market Commentary: Hertz spikes on rights offering; Frontier mixed in telecom space
|
6/12/2019 | HY | Market Commentary: Frontier lower on analyst downgrade; Teva down on settlement news
|
6/12/2019 | DD | Market Commentary: Frontier lower on analyst downgrade; Teva down on settlement news
|
6/11/2019 | HY | Market Commentary: Hexion mixed as term loan prepped; Legacy Reserves down on bankruptcy talk
|
6/11/2019 | DD | Market Commentary: Hexion mixed as term loan prepped; Legacy Reserves down on bankruptcy talk
|
6/7/2019 | HY | Market Commentary: Frontier lower on board appointments; Teva mixed as ratings downgraded
|
6/7/2019 | DD | Market Commentary: Frontier lower on board appointments; Teva mixed as ratings downgraded
|
6/7/2019 | BKCVEM | Fitch downgrades Teva
|
6/6/2019 | HY | Market Commentary: Intelsat rises as new issue prices; Mallinckrodt slumps in settlement reaction
|
6/6/2019 | DD | Market Commentary: Intelsat rises as new issue prices; Mallinckrodt slumps in settlement reaction
|
6/5/2019 | HY | Market Commentary: Mallinckrodt better after settling suit; L Brands down as tender offer starts
|
6/5/2019 | DD | Market Commentary: Mallinckrodt better after settling suit; L Brands down as tender offer starts
|
6/4/2019 | HY | Market Commentary: PetSmart up as Chewy valuation increases; Teva rises in pharma space
|
6/4/2019 | DD | Market Commentary: PetSmart up as Chewy valuation increases; Teva rises in pharma space
|
6/3/2019 | BKCVDDEMIGPV | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
6/3/2019 | HY | Market Commentary: Multi-Color, Grubhub on tap; Neiman Marcus, GCI price; Teva in focus, gains; Altice up
|
6/3/2019 | HY | Market Commentary: Teva better after analyst upgrade; Navios mixed on debt offering
|
6/3/2019 | DD | Market Commentary: Teva better after analyst upgrade; Navios mixed on debt offering
|
6/3/2019 | CV | Market Commentary: New Mountain taps 5.75% notes; Cypress Semiconductor in focus; ON Semiconductors better
|
5/31/2019 | HY | Market Commentary: U.S. Steel down on tariff news; Teva mixed after negative week
|
5/31/2019 | DD | Market Commentary: U.S. Steel down on tariff news; Teva mixed after negative week
|
5/30/2019 | HY | Market Commentary: PetSmart improves on Chewy valuation; Teva loses on analyst scrutiny
|
5/30/2019 | DD | Market Commentary: PetSmart improves on Chewy valuation; Teva loses on analyst scrutiny
|
5/30/2019 | SP | New Issue: CIBC sells $370,000 Raymond James Healthcare Top Selections notes on 15 stocks
|
5/30/2019 | SP | New Issue: CIBC sells $1.64 million Raymond James Healthcare Top Selections notes on 15 stocks
|
5/29/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
5/29/2019 | HY | Market Commentary: CNO Financial prices; Frontier gains; Teva’s downward spiral continues; CRC drops
|
5/29/2019 | HY | Market Commentary: Frontier gains on asset sale news; Teva loses in settlement reaction
|
5/29/2019 | DD | Market Commentary: Frontier gains on asset sale news; Teva loses in settlement reaction
|
5/28/2019 | HY | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
5/28/2019 | BKCVDDEMIGPV | Market Commentary: CNO Financial, GoDaddy on tap; Fiat up on merger; Teva drops post settlement
|
5/28/2019 | HY | Market Commentary: Teva lower as company settles suit; Navios mixed amid debt swap
|
5/28/2019 | DD | Market Commentary: Teva lower as company settles suit; Navios mixed amid debt swap
|
5/24/2019 | HY | Market Commentary: Exela continues on downward track; Ensco Rowan sees upward push
|
5/24/2019 | DD | Market Commentary: Exela continues on downward track; Ensco Rowan sees upward push
|
5/23/2019 | HY | Market Commentary: Exela pushed into distressed territory; L Brands rises after earnings report
|
5/23/2019 | DD | Market Commentary: Exela pushed into distressed territory; L Brands rises after earnings report
|
5/22/2019 | HY | Market Commentary: Mallinckrodt lower on ratings downgrade; DISH mixed after acquiring assets
|
5/22/2019 | DD | Market Commentary: Mallinckrodt lower on ratings downgrade; DISH mixed after acquiring assets
|
5/21/2019 | HY | Market Commentary: Mallinckrodt dives after legal move; J.C. Penney down post-earnings
|
5/21/2019 | DD | Market Commentary: Mallinckrodt dives after legal move; J.C. Penney down post-earnings
|
5/20/2019 | HY | Market Commentary: Alta Mesa lower on SEC investigation; U.S. Steel negative after trade news
|
5/20/2019 | DD | Market Commentary: Alta Mesa lower on SEC investigation; U.S. Steel negative after trade news
|
5/17/2019 | HY | Market Commentary: Dean Foods down after ratings downgrade; U.S. Steel lower on trade news
|
5/17/2019 | DD | Market Commentary: Dean Foods down after ratings downgrade; U.S. Steel lower on trade news
|
5/17/2019 | SP | New Issue: UBS prices $1 million trigger phoenix autocallables linked to Teva
|
5/16/2019 | HY | Market Commentary: U.S. Steel rises despite trade climate; Navios gains after asset manager buys stake
|
5/16/2019 | DD | Market Commentary: U.S. Steel rises despite trade climate; Navios gains after asset manager buys stake
|
5/15/2019 | BKCVDDEMIGPV | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure
|
5/15/2019 | HY | Market Commentary: Transocean prices; Berry on tap; VistaJet active; Teva, Commscope under pressure; BWAY gains
|
5/15/2019 | HY | Market Commentary: Teva lower on continued scrutiny; Chaparral Energy drops after downgrade
|
5/15/2019 | DD | Market Commentary: Teva lower on continued scrutiny; Chaparral Energy drops after downgrade
|
5/14/2019 | HY | Market Commentary: Intelsat rises on 5G development; Halcon gains despite ratings downgrade
|
5/14/2019 | DD | Market Commentary: Intelsat rises on 5G development; Halcon gains despite ratings downgrade
|
5/13/2019 | HY | Market Commentary: Teva loses as legal troubles mount; Weatherford drops as bankruptcy expected
|
5/13/2019 | DD | Market Commentary: Teva loses as legal troubles mount; Weatherford drops as bankruptcy expected
|
5/13/2019 | BKCVDDEMIGPV | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
5/13/2019 | HY | Market Commentary: Eldorado on tap; Bausch Health weakens; Charter below par; Weatherford, Teva down
|
5/7/2019 | HY | Market Commentary: Dean Foods better despite negative earnings; Mallinckrodt mixed on earnings beat
|
5/7/2019 | DD | Market Commentary: Dean Foods better despite negative earnings; Mallinckrodt mixed on earnings beat
|
5/3/2019 | DD | Market Commentary: California Resources mixed post-earnings; PetSmart jumps as outlook changed
|
5/3/2019 | HY | Market Commentary: California Resources mixed post-earnings; PetSmart jumps as outlook changed
|
5/2/2019 | HY | Market Commentary: Ensco Rowan, PG&E slip post-earnings; Teva Pharmaceutical lower after mixed earnings results
|
5/2/2019 | DD | Market Commentary: Ensco Rowan, PG&E slip post-earnings; Teva Pharmaceutical lower after mixed earnings results
|
4/25/2019 | HY | Market Commentary: California Resources dips; Adient rises as subsidiary prices new issue
|
4/25/2019 | DD | Market Commentary: California Resources dips; Adient rises as subsidiary prices new issue
|
4/23/2019 | HY | Market Commentary: Air Methods higher as earnings trickle out; PG&E higher as new director named
|
4/23/2019 | DD | Market Commentary: Air Methods higher as earnings trickle out; PG&E higher as new director named
|
4/10/2019 | HY | Market Commentary: Rite Aid mixed as company decides on stock split; Intelsat lower on satellite problems
|
4/10/2019 | DD | Market Commentary: Rite Aid mixed as company decides on stock split; Intelsat lower on satellite problems
|
4/10/2019 | SP | New Issue: UBS prices $140,000 airbag yield optimization notes linked to Teva
|
4/10/2019 | BK | Teva obtains new $2.3 billion revolver in tranches due 2022, 2024
|
3/28/2019 | HY | Market Commentary: PG&E mixed as creditors propose bankruptcy exit plan; Endo off on early tender results
|
3/28/2019 | DD | Market Commentary: PG&E mixed as creditors propose bankruptcy exit plan; Endo off on early tender results
|
3/26/2019 | HY | Market Commentary: Endo up as sector peer settles lawsuit; Bed Bath & Beyond rises as investors push CEO exit
|
3/26/2019 | DD | Market Commentary: Endo up as sector peer settles lawsuit; Bed Bath & Beyond rises as investors push CEO exit
|
3/26/2019 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
3/22/2019 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
3/14/2019 | HY | Market Commentary: Endo notes positive as company begins debt refinancing; PHI issues down on maturity fears
|
3/14/2019 | DD | Market Commentary: Endo notes positive as company begins debt refinancing; PHI issues dip over maturity fears
|
3/12/2019 | SP | BofA to price contingent income autocallables tied to three stocks
|
2/26/2019 | HY | Market Commentary: Alta Mesa notes crash after financial reporting news; Windstream issues gain
|
2/26/2019 | DD | Market Commentary: Alta Mesa notes crash after financial reporting news; Windstream issues gain as bankruptcy process starts
|
2/22/2019 | HY | Market Commentary: Windstream drops on bankruptcy concerns; Halcon falls following CEO departure
|
2/22/2019 | DD | Market Commentary: Windstream drops on bankruptcy concerns; Halcon falls following CEO departure
|
2/21/2019 | SP | New Issue: UBS prices $106,000 buffered return optimization securities linked to Teva Pharmaceutical
|
2/20/2019 | HY | Market Commentary: Intelsat rises despite earnings miss; FirstEnergy gains as earnings beat estimates
|
2/20/2019 | DD | Market Commentary: Intelsat rises despite earnings miss; FirstEnergy gains as earnings beat estimates
|
2/19/2019 | HY | Market Commentary: Windstream notes crash after legal battle lost; PHI issues drop as pressure mounts
|
2/19/2019 | DD | Market Commentary: Windstream notes crash after legal battle lost; PHI issues drop as pressure mounts on maturity
|
2/15/2019 | HY | Market Commentary: Ensco, Rowan notes gain as regulator approves merger; Univision issues recover
|
2/15/2019 | DD | Market Commentary: Ensco, Rowan notes gain as regulator approves merger; Univision issues recover after earnings release
|
2/15/2019 | BKCVEM | S&P revises Teva view to negative
|
2/14/2019 | HY | Market Commentary: McDermott notes continue fall after cost overrun report; Univision issues leak
|
2/14/2019 | DD | Market Commentary: McDermott notes continue fall after cost overrun report; Univision issues leak after poor earnings
|
2/14/2019 | BKCVEM | S&P lowers Teva view to negative
|
2/13/2019 | HY | Market Commentary: Teva notes drop after Q4 profit loss; Diebold issues surge after revenue tops expectations
|
2/13/2019 | DD | Market Commentary: Teva notes drop after Q4 profit loss; Diebold issues surge after better than expected revenue
|
1/14/2019 | HY | Market Commentary: PG&E crashes on bankruptcy news; Ensco mixed as company seeks to alter Rowan deal
|
1/14/2019 | DD | Market Commentary: PG&E crashes on bankruptcy news; Ensco mixed as company seeks to alter Rowan deal
|
1/4/2019 | BKCVDDEMIGPV | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
1/4/2019 | HY | Market Commentary: Risk-on sentiment returns; CDX sees largest single-day gain in four years; energy outperforms
|
1/3/2019 | BKCVDDEMIGPV | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Teva up
|
1/3/2019 | HY | Market Commentary: No new deals in sight; trading volume light; Western Digital active; Qorvo drops; Xerox, Teva gain
|
12/31/2018 | DD | Market Commentary: Outlook 2019: Energy to stabilize; retailers to divide online market; telecom weakness eyed
|
12/7/2018 | HY | Market Commentary: Mallinckrodt notes move lower as market reacts to spinoff news; Neiman Marcus down
|
12/7/2018 | DD | Market Commentary: Mallinckrodt notes move lower as market reacts to spinoff news; Neiman Marcus down on sales report
|
11/1/2018 | BKBWCVEMHY | Israel’s Teva is using majority of cash flow to reduce leverage to 3x
|
10/11/2018 | HY | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
10/11/2018 | BKCVDDEMIGPV | Market Commentary: Millicom prices; TransDigm rises on acquisition; energy mixed; Teva Pharaceutical improves
|
10/10/2018 | CV | Market Commentary: Convertibles calm as equities sell off; Granite Point prices; Karyopharm stock plunges
|
9/25/2018 | CV | Market Commentary: Convertibles market eyes CenterPoint Energy offering; Chesapeake Energy, Novavax active
|
9/25/2018 | CV | Market Commentary: Morning Commentary: Market eyes CenterPoint Energy offering; Chesapeake Energy active
|
9/18/2018 | EMHYLM | Israel’s Teva to buy some 1.7%, 3/8% notes in oversubscribed tender
|
9/14/2018 | BWEMHY | Teva sees slump in profits, rise in debt due to Copaxone competition
|
9/11/2018 | SP | New Issue: Credit Suisse sells $1 million autocallable reverse convertibles tied to three stocks
|
9/4/2018 | EMHYLM | Israel’s Teva to pay up to $400 million in tenders for three issues
|
8/29/2018 | SP | New Issue: UBS prices $654,000 trigger phoenix autocallables linked to Teva
|
8/29/2018 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Teva
|
8/20/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
8/15/2018 | BKCVEM | Fitch affirms Teva Pharmaceutical
|
7/27/2018 | HY | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
7/27/2018 | BKCVDDEMIGPV | Market Commentary: Hi-Crush prices, euro primary active; Party City’s new issue lower; Teva slides
|
7/26/2018 | HY | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
7/26/2018 | BKCVDDEMIGPV | Market Commentary: Party City prices; Teva improves; Aleris acquired; SuperValu bought; funds off $548 million
|
7/26/2018 | SP | New Issue: UBS prices $425,000 trigger phoenix autocallables linked to Teva
|
7/20/2018 | HY | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
7/20/2018 | BKCVDDEMIGPV | Market Commentary: Comstock prices; Bruin carried over; secondary trading light; IHS Markit eyed; Teva active
|
7/9/2018 | CV | Market Commentary: Palo Alto Networks to sell $1.5 billion convertible; Teva active; Ironwood a concern
|
7/2/2018 | HY | Market Commentary: Primary, secondary quiet pre-holiday; recent deals unchanged; Teva, HCA active; ATD gains
|
6/26/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
6/22/2018 | SP | New Issue: UBS prices $705,000 trigger phoenix autocallables linked to Teva
|
5/18/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
4/27/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
4/5/2018 | SP | New Issue: UBS prices $350,000 trigger phoenix autocallables linked to Teva
|
3/16/2018 | HY | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
3/16/2018 | BKCVDDEMIGPV | Market Commentary: Tullow, Husky lead busy primary; Mattel trades on Toys shutdown; Teva still trades under par
|
3/13/2018 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
3/13/2018 | BWEMHY | Teva’s upsized bond sale goes ‘very well’; pricing on low end of talk
|
3/7/2018 | HY | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up ahead of deal
|
3/7/2018 | HY | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up ahead of deal
|
3/7/2018 | BKCVDDEMIGPV | Market Commentary: Upsized Teva megadeal prices; new Ball notes busiest; CIT trades up; Frontier mostly up
|
3/7/2018 | EMHY | New Issue: Teva Pharmaceutical sells upsized $4.5 billion equivalent notes in four tranches
|
3/7/2018 | HY | Market Commentary: Morning Commentary: CIT subordinated paper soars into secondary; Teva launches upsized $4.5 billion
|
3/7/2018 | EMHY | Israel’s Teva launches upsized $4.5 billion four-part bond deal; pricing expected Wednesday
|
3/6/2018 | HY | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price; Teva on tap
|
3/6/2018 | BKCVDDEMIGPV | Market Commentary: Three-part CIT drive-by leads deal parade; Ball, William Lyons, Buena Vista also price
|
3/6/2018 | EM | Market Commentary: Senegal, KDB price notes; Sharjah prices $1 billion sukuk; Union National brings notes
|
3/6/2018 | EMHY | Teva Pharmaceutical sets price talk in $3.5 billion four-part deal; books close Wednesday
|
3/2/2018 | HY | Market Commentary: Smaller, restructured Meritage caps $3.49 billion primary week; New Enterprise notes busy
|
2/28/2018 | SP | New Issue: Barclays prices $15 million airbag autocallable yield notes tied to Teva
|
2/28/2018 | BKCVEM | S&P rates Teva notes BB
|
2/28/2018 | BKCVEM | Moody’s applies Ba2 to Teva notes
|
2/28/2018 | EMHY | Teva Pharmaceutical sets roadshow for $3.5 billion equivalent four-part bullet notes
|
2/26/2018 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallables linked to Teva
|
2/23/2018 | SP | New Issue: UBS prices $290,000 trigger phoenix autocallables linked to Teva
|
2/16/2018 | SP | New Issue: UBS prices $150,000 trigger autocallables linked to Teva
|
2/8/2018 | BK | S&P downgrades Teva, debt
|
2/5/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
2/2/2018 | BK | S&P might downgrade Teva
|
2/1/2018 | HY | Market Commentary: Upsized JBS prices, also Indigo, Oceaneering; new Indigo firms; energy up as crude gains
|
2/1/2018 | BK | Teva amends covenants in credit agreements for added flexibility
|
1/31/2018 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallables linked to Teva
|
1/26/2018 | SP | New Issue: UBS prices $799,981 7.37% trigger yield optimization notes linked to Teva
|
1/24/2018 | SP | New Issue: UBS prices $315,000 trigger autocallables linked to Teva Pharmaceutical
|
1/18/2018 | SP | New Issue: UBS prices $596,000 trigger phoenix autocallables linked to Teva Pharmaceutical
|
1/18/2018 | SP | New Issue: UBS prices $440,000 trigger phoenix autocallables linked to Teva Pharmaceutical
|
1/18/2018 | SP | New Issue: UBS prices $130,000 trigger phoenix autocallables linked to Teva Pharmaceutical
|
1/18/2018 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Teva Pharmaceutical
|
1/17/2018 | HY | Market Commentary: Noble deal upsizes; RCN Grande, Itron add-on, split-rated Toll also price; Tuesday deals trade actively
|
1/17/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
1/16/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
1/12/2018 | BKCVEM | Moody’s downgrades Teva to Ba2
|
1/10/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables on Teva Pharmaceutical
|
1/10/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
12/29/2017 | SP | New Issue: Credit Suisse prices $1.36 million 12.85% contingent coupon autocalls tied to stocks
|
12/27/2017 | SP | New Issue: UBS prices $145,000 trigger phoenix autocallables linked to Teva
|
12/18/2017 | SP | New Issue: UBS prices $645,000 trigger autocallables linked to Teva Pharmaceutical
|
12/15/2017 | CV | Market Commentary: Teva in focus, Bristow still going strong, adios to Intel
|
12/14/2017 | CV | Market Commentary: Bristow gains then eases a little, Teva better on restructuring; Cobalt bankruptcy no surprise
|
12/14/2017 | BKBWCVHYIG | Teva to use all available cash flow to cut debt until end of 2020
|
12/14/2017 | BKCVEMIG | Moody’s reviews Teva Pharmaceutical
|
12/14/2017 | CV | Market Commentary: Morning Commentary: Bristow makes gains on market debut, Teva active
|
12/12/2017 | SP | New Issue: Credit Suisse sells $500,000 autocallable yield notes linked to Teva
|
12/11/2017 | SP | New Issue: UBS prices $1.28 million trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
11/27/2017 | CV | Market Commentary: Square tumbles after record high, health care companies active in post-holiday lull
|
11/27/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
11/21/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Teva
|
11/13/2017 | CV | Market Commentary: Rambus, Quotient announce new deals, Square Inc. jumps, recent issues in demand
|
11/13/2017 | CV | Market Commentary: Morning Commentary: Square Inc. dominates early trades, Micron continues upwards climb
|
11/6/2017 | BKCVEMIG | Fitch downgrades Teva to BB
|
11/3/2017 | BKCVEMIG | S&P revises Teva to negative
|
10/18/2017 | SP | New Issue: UBS prices $125,000 trigger autocallables linked to Teva Pharmaceutical
|
10/12/2017 | SP | New Issue: UBS prices $160,000 trigger phoenix autocallables linked to Teva
|
10/12/2017 | SP | New Issue: UBS prices $643,000 trigger phoenix autocallables linked to Teva
|
10/12/2017 | SP | New Issue: UBS prices $465,000 trigger phoenix autocallables linked to Teva
|
10/5/2017 | CV | Market Commentary: Convertibles buyers step in to select names; supply remains tight; Navistar 4.5s gain
|
10/4/2017 | CV | Market Commentary: Convertibles primary market quiet again; Tesla convertibles expand in active trade; Teva lower
|
9/25/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
9/20/2017 | BKCVEMIG | S&P downgrades Teva
|
9/19/2017 | CV | Market Commentary: Sibanye brings new issue; Marriott Vacations, Maxwell add to calendar; Meritor on tap
|
9/19/2017 | BK | Teva amends credit facilities to provide greater covenant flexibility
|
9/19/2017 | CV | Market Commentary: Morning Commentary: Sibanye Gold bringing new issue; Meritor in the works; Teva trades again
|
9/13/2017 | CV | Market Commentary: Workday prices in the middle of talk, trades above par; Wayfair’s issue adds to gains
|
9/12/2017 | CV | Market Commentary: Wayfair’s new 0.375% convertibles trade up in heavy volume; Workday on tap; Teva firm
|
9/11/2017 | CV | Market Commentary: Wayfair, Workday add convertibles to calendar; Teva improves as new CEO named; Tesla up
|
9/11/2017 | CV | Market Commentary: Morning Commentary: Wayfair adds to calendar; Teva improves as new CEO named
|
8/22/2017 | CV | Market Commentary: II-VI plans new Rule 144A deal; Jazz edges above issue price; Red Hat busy; Teva assets eyed
|
8/4/2017 | EM | S&P downgrades Congo
|
8/4/2017 | CV | Market Commentary: Electronics for Imaging bonds drop on accounting troubles; Teva convertibles falter
|
8/4/2017 | BKCVIG | Fitch downgrades Teva to BBB-
|
8/4/2017 | BKCVEMIG | Moody's downgrades Teva
|
7/27/2017 | CV | Market Commentary: U.S. convertibles mixed as earnings in focus; recently priced Teladoc adds dollar neutral
|
7/13/2017 | CV | Market Commentary: Teva mandatories gain with stock on CEO chatter; Cobalt, Weatherford convertibles firm
|
7/13/2017 | CV | Market Commentary: Morning Commentary: Teva mandatories gain with stock on CEO chatter; Great Plains also firms
|
6/20/2017 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallables linked to Teva
|
5/23/2017 | SP | New Issue: JPMorgan prices $9.19 million contingent income autocallables linked to Teva
|
5/12/2017 | SP | JPMorgan to price contingent income autocallables linked to Teva ADS
|
4/25/2017 | SP | New Issue: UBS prices $152,000 trigger phoenix autocallables linked to Teva
|
3/27/2017 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Teva Pharmaceutical
|
3/7/2017 | SP | New Issue: RBC sells $1.44 million contingent coupon barrier autocallables on Teva
|
2/21/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
2/3/2017 | BKCVEMIG | S&P: Teva Pharmaceutical outlook to negative
|
1/31/2017 | CV | Market Commentary: Greenbrier deal set to price; Teva convertibles in decline as patents nixed; Rayonier lower
|
1/31/2017 | CV | Market Commentary: Morning Commentary: Greenbrier deal set to price; Teva convertibles in decline as patents nixed
|
1/27/2017 | SP | New Issue: UBS prices $430,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
1/3/2017 | SP | New Issue: UBS prices $405,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
12/30/2016 | SP | New Issue: GS Finance prices $5.01 million trigger autocallable contingent yield notes on Teva
|
12/22/2016 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable linked to Teva
|
12/21/2016 | SP | GS plans trigger autocallable contingent yield notes linked to Teva
|
12/16/2016 | SP | New Issue: UBS prices $550,000 trigger phoenix autocallables linked to Teva
|
12/14/2016 | SP | New Issue: UBS prices $105,000 trigger phoenix autocallables linked to Teva
|
12/14/2016 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Teva
|
12/14/2016 | SP | New Issue: UBS prices $213,000 trigger phoenix autocallables linked to Teva
|
12/14/2016 | SP | New Issue: UBS prices $1.2 million trigger phoenix autocallables linked to Teva
|
12/13/2016 | SP | New Issue: UBS prices $500,000 trigger phoenix autocallable optimization securities linked to Teva Pharmaceutical
|
11/22/2016 | SP | New Issue: Morgan Stanley prices $6.24 million trigger participation notes linked to 45 stocks
|
10/13/2016 | CV | Market Commentary: Teva convertibles rise on swap; Fluidigm, Illumina pressured; Tesla bounces; DISH heavy
|
9/1/2016 | SP | New Issue: JPMorgan prices $2.96 million trigger autocallable contingent yield notes tied to Teva
|
8/24/2016 | SP | JPMorgan plans trigger autocallable contingent yield notes linked to Teva
|
8/23/2016 | SP | JPMorgan plans trigger autocallable contingent yield notes tied to Teva
|
8/2/2016 | BKCVEMIG | Moody’s downgrades Teva to Baa2
|
7/22/2016 | BKCVEMIG | Fitch rates Teva bonds BBB
|
7/21/2016 | EM | New Issue: Israel’s Teva Pharmaceutical sells CHF 1 billion notes in three parts
|
7/20/2016 | EMHYMUPFPV | Market Commentary: Primary action thins; Citi subordinated notes mixed; Teva stronger; credit spreads firm
|
7/20/2016 | IG | Market Commentary: Primary action thins; Citigroup subordinated notes mixed; Teva stronger; credit spreads firm
|
7/20/2016 | EM | New Issue: Israel’s Teva Pharmaceutical Finance prices €4 billion of notes in three tranches
|
7/20/2016 | BKCVEMIG | Fitch downgrades Teva, rates bond BBB
|
7/20/2016 | IG | Market Commentary: Morning Commentary: Teva notes tighten; Citigroup paper unchanged; Libor yield hits 70 bps
|
7/19/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
7/18/2016 | EMHYMUPFPV | Market Commentary: Teva prices $15 billion; Citi, Wells Fargo tap market; bonds mixed; credit spreads improve
|
7/18/2016 | IG | Market Commentary: Teva prices $15 billion; Citi, Wells Fargo tap market; bonds mixed; credit spreads improve
|
7/18/2016 | EMIG | New Issue: Israel’s Teva Pharmaceutical details pricing of $15 billion of notes in six tranches
|
7/18/2016 | BKCVEMIG | S&P rates Teva notes BBB
|
7/18/2016 | BKCVEMIG | Moody’s rates Teva notes Baa2
|
7/18/2016 | IG | Market Commentary: Morning Commentary: Teva offering in deal pipeline; JPMorgan eases; credit spreads unchanged
|
7/18/2016 | EMIG | Teva Pharmaceuticals in the market with fixed-, floating-rate notes
|
7/13/2016 | EMHYMUPFPV | Market Commentary: Japan Bank, Bank of Montreal, International Finance in primary; Anheuser-Busch flat on day
|
7/13/2016 | IG | Market Commentary: Japan Bank, Bank of Montreal, International Finance in primary; Anheuser-Busch flat on day
|
7/13/2016 | EMIG | Teva sets investor call dates ahead of more than $20 billion equivalent of debt offerings
|
7/13/2016 | BKBWEMIG | Teva planned net debt funding for Allergan purchase down by $4 billion
|
7/13/2016 | BKCVEMIG | S&P downgrades Teva
|
7/13/2016 | EMIG | Teva expected to tap markets for more than $20 billion of debt to fund acquisition
|
7/12/2016 | SP | New Issue: RBC prices $1.9 million of phoenix autocallables linked to Teva Pharmaceutical
|
5/17/2016 | SP | New Issue: JPMorgan prices $676,000 contingent interest autocallables linked to pharma stocks
|
5/9/2016 | PP | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
5/9/2016 | CV | Market Commentary: Teva makes outright gains after positive earnings; Illumina flat as health care rallies
|
5/9/2016 | CV | Market Commentary: Morning Commentary: Teva up a little in line with shares after posting decent earnings
|
5/6/2016 | PP | Market Commentary: Teva bonds improve on lower shares; Allergan mandatory drops; Chesapeake extends gains
|
5/6/2016 | CV | Market Commentary: Teva bonds improve on lower shares; Allergan mandatory drops; Chesapeake extends gains
|
5/6/2016 | CV | Market Commentary: Morning Commentary: Teva bonds move higher in active trade; Endo International weighs on drug sector
|
5/5/2016 | SP | JPMorgan plans autocallable contingent interest notes on three stocks
|
3/3/2016 | PP | Market Commentary: Herbalife lower on overstated member metric; Ctrip.com mixed on swap; Ciena drops
|
3/3/2016 | CV | Market Commentary: Herbalife lower on overstated member metric; Ctrip.com mixed on swap; Ciena drops
|
3/3/2016 | CV | Market Commentary: Morning Commentary: Herbalife lower on overstated new member metric; market remains better-bid
|
1/11/2016 | CV | Market Commentary: Energy-related convertibles move lower; other sectors hold in on swap; Depomed drops
|
1/11/2016 | CV | Market Commentary: Morning Commentary: Depomed convertibles, shares lower; health care in focus during conference
|
1/4/2016 | CV | Teva greenshoe ups 7% mandatory convertible preferreds to $3.7 billion
|
12/8/2015 | CV | Market Commentary: Convertibles weak as oil roils markets; Chesapeake down again; Harmonic looks cheap
|
12/3/2015 | PP | Market Commentary: Teva contracts on swap; new Inphi adds 0.5 point; Pandora, Vitamin Shoppe deals look cheap
|
12/3/2015 | CV | Market Commentary: Teva contracts on swap; new Inphi adds 0.5 point; Pandora, Vitamin Shoppe deals look cheap
|
12/3/2015 | CV | Market Commentary: Morning Commentary: New Teva lags; Inphi trades better; Pandora, Vitamin Shoppe deals look cheap
|
12/3/2015 | CV | New Issue: Teva prices $3.38 billion mandatory convertible preferreds to yield 7%, up 20%
|
12/2/2015 | PP | Market Commentary: Upsized Nuance edges up in trade; planned Inphi looks cheap; Teva on tap; Pandora launches
|
12/2/2015 | CV | Market Commentary: Upsized Nuance edges up in trade; planned Inphi looks cheap; Teva on tap; Pandora launches
|
12/1/2015 | PP | Market Commentary: Planned Nuance convertibles slightly cheap; Teva deal timing accelerated; Inphi on tap
|
12/1/2015 | CV | Market Commentary: Planned Nuance convertibles slightly cheap; Teva deal timing accelerated; Inphi on tap
|
12/1/2015 | CV | Teva accelerates pricing of $3.38 billion mandatory convertible preferreds to Wednesday
|
11/30/2015 | PP | Market Commentary: Teva Pharmaceutical, Nuance launch large deals; existing Teva quiet; market eyes month-end
|
11/30/2015 | CV | Market Commentary: Teva Pharmaceutical, Nuance launch large deals; existing Teva quiet; market eyes month-end
|
11/30/2015 | CV | Market Commentary: Morning Commentary: Planned Teva Pharmaceutical deal looks ‘cheap’; existing Teva quiet
|
11/30/2015 | CV | Teva Pharmaceutical plans $3.38 billion mandatory convertible to yield 6.75%-7.25%, up 17.5%-22.5%
|
11/25/2015 | BKCVEMIG | S&P rates Teva loan BBB+
|
11/18/2015 | BK | Teva signs $5 billion term loan agreement, $4.5 billion revolver
|
11/5/2015 | CV | Israel’s Teva shareholders OK mandatory convertible preferred issue
|
8/3/2015 | BKEMIG | Israel’s Teva details commitments for $33.75 billion in facilities
|
7/31/2015 | BKEMIG | Israel’s Teva gets financing commitments for up to $33.75 billion
|
7/28/2015 | PP | Market Commentary: Teva debt active; Micron, Intel firm on new chip; Whiting bonds rebound ahead of earnings
|
7/28/2015 | CV | Market Commentary: Teva debt active; Micron, Intel firm on new chip; Whiting bonds rebound ahead of earnings
|
7/28/2015 | BKCVEMIG | S&P lowers Teva Pharmaceutical
|
7/28/2015 | CV | Market Commentary: Morning Commentary: Teva debt remains active; Whiting bonds rebound; Alpha issue set to mature
|
7/27/2015 | BKBWEMIGLM | Teva Pharmaceuticals to obtain up to $27 billion of debt to buy Allergan’s generics business
|
7/27/2015 | PP | Market Commentary: Teva convertibles soar on Allergan bid; Micron, Intel to hold press event; bonds higher
|
7/27/2015 | CV | Market Commentary: Teva convertibles soar on Allergan bid; Micron, Intel to hold press event; bonds higher
|
7/27/2015 | BKCVEMIG | Moody’s cuts Teva Pharmaceutical to Baa1
|
7/27/2015 | CV | Market Commentary: Morning Commentary: Teva convertibles rise on Allergan bid; trader expects IGI to remain firm
|
7/2/2015 | PP | Market Commentary: Convertibles quiet heading into holiday weekend; Teslas improve on strong deliveries
|
7/2/2015 | CV | Market Commentary: Convertibles quiet heading into holiday weekend; Teslas improve on strong deliveries
|
4/22/2015 | BK | S&P downgrades Chromaflo
|
4/22/2015 | BK | S&P downgrades Chromaflo
|
4/22/2015 | BKCVEMIG | Fitch: Teva on watch after merger news
|
4/22/2015 | BKCVEMIG | S&P: Teva on watch after Mylan deal announced
|
4/21/2015 | PP | Market Commentary: Mylan moves up in line on Teva bid; Lam Research jumps outright; Iconix continues to trade
|
4/21/2015 | CV | Market Commentary: Mylan moves up in line on Teva bid; Lam Research jumps outright; Iconix continues to trade
|
4/21/2015 | BKCVEMIG | Moody's changes Teva outlook to negative
|
4/21/2015 | CV | Market Commentary: Morning Commentary: Mylan, Teva move up in line on merger deal news; Intel slips
|
4/16/2015 | PP | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
4/16/2015 | CV | Market Commentary: SanDisk lower outright, edges up on swap; Teva below parity; planned Pernix looks cheap
|
4/9/2015 | PP | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
4/9/2015 | CV | Market Commentary: Qihoo, other Asian internet names up again in active trade; Isis improves; Teva at parity
|
4/8/2015 | CV | Market Commentary: Qihoo bonds rise outright, on swap with higher Asian stocks; Mylan trades up outright
|
4/7/2015 | CV | Market Commentary: Convertibles firmer; Ctrip, Twitter improve on swap; SanDisk bonds active; Greenbrier eyed
|
3/31/2015 | BKCVEMIG | Moody's: Teva unchanged
|
3/30/2015 | PP | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
3/30/2015 | CV | Market Commentary: Horizon Pharma jumps outright, adds on hedge; health-care bid remains strong; Intel active
|
3/30/2015 | CV | Market Commentary: Morning Commentary: Horizon Pharma jumps outright; health care bid remains strong; Intel active
|
3/24/2015 | HYIG | Market Commentary: New deal from Teva Pharmaceuticals; risk aversion grows; Asia mixed, Lat-Am weakens
|
3/24/2015 | EM | Market Commentary: New deal from Teva Pharmaceuticals; risk aversion grows; Asia mixed, Lat-Am weakens
|
3/24/2015 | EM | New Issue: Israel’s Teva Pharmaceutical sells €2 billion notes due in 2023, 2027
|
3/24/2015 | BKCVEMIG | Moody's rates Teva notes A3
|
3/24/2015 | BKCVEMIG | S&P rates Teva notes A-
|
3/24/2015 | BKCVEMIG | Fitch assigns BBB+ to Teva bond
|
3/24/2015 | EM | Israel’s Teva Pharmaceutical mandates four bookrunners for euro notes
|
3/11/2015 | EM | Market Commentary: Petronas, Panama, Millicom sell notes; Russia, Turkey, Asia weaken; Braskem tied to scandal
|
3/11/2015 | EM | Israel’s Teva Pharmaceutical to issue euro-denominated notes
|
2/27/2015 | EMIGLM | Israel’s Teva ups tender purchase amount to $1.3 billion; pricing set
|
2/19/2015 | BK | Fitch upgrades JetBlue
|
2/19/2015 | BKCVEMIG | Moody’s revises Teva to stable
|
2/12/2015 | EMIGLM | Teva Pharmaceutical tenders for up to $1 billion of four note series
|
9/9/2014 | SP | New Issue: Barclays prices $10.34 million 4.5% Yeelds linked to Teva
|
3/7/2014 | SP | New Issue: Barclays prices $10.02 million 6.18% Yeelds linked to Teva
|
1/21/2014 | CV | Market Commentary: NQ Mobile, Teva Pharmaceutical better on swap; Yandex in trade; YRC Worldwide in focus
|
12/12/2013 | SP | New Issue: Barclays prices $10.03 million 4.9% Yeelds tied to Teva Pharmaceutical
|
12/11/2013 | BKCVEM | Fitch downgrades Teva
|
6/13/2013 | BKCVEM | Moody's: Teva view to negative
|
3/1/2013 | EMIGLM | Israel's Teva Pharmaceutical calls $500 million 5.55% notes due 2016
|
12/18/2012 | EM | Teva Pharmaceutical Finance to redeem $1 billion senior notes due 2014
|
12/18/2012 | IGLM | Teva Pharmaceutical Finance to redeem $1 billion senior notes due 2014
|
12/18/2012 | BK | Teva gets expanded $3 billion five-year revolver with Citi and HSBC
|
12/17/2012 | IG | Market Commentary: Midday Commentary: Primary issuance slows; Teva Pharmaceutical notes trading weaker
|
12/17/2012 | IG | Market Commentary: Precision Castparts, Florida Power sell as pipeline slows; Citi weakens; Teva bonds active
|
12/14/2012 | IG | Market Commentary: Market Commentary: Strong tone caps off week's trading; Teva notes tighten in secondary
|
12/14/2012 | IG | Market Commentary: Up to $10 billion of new bonds seen in coming week before year-end wind-down; Teva notes firm
|
12/13/2012 | EM | Israel's Teva Pharmaceutical units selling benchmark senior notes due 2020, 2022 on Thursday
|
12/13/2012 | EM | New Issue: Teva units price $2 billion of senior notes due 2020, 2022
|
12/13/2012 | BK | Teva Pharmaceutical to pay down $700 million loan via note offerings
|
12/13/2012 | IG | Israel's Teva Pharmaceutical units selling benchmark senior notes due 2020, 2022 on Thursday
|
12/13/2012 | BKCVEM | Fitch rates Teva notes A-
|
12/13/2012 | IG | New Issue: Teva units price $2 billion of senior notes due 2020, 2022
|
12/13/2012 | CVEM | Moody's rates Teva notes A3
|
12/13/2012 | IG | Market Commentary: Teva sells two maturities, joined by HSBC, Williams, NewMarket; secondary tone weaker
|
12/13/2012 | CVEM | S&P rates Teva notes A-
|
12/13/2012 | IGLM | Teva Pharmaceutical to redeem $1 billion 1.7% notes via new offerings
|
12/3/2012 | CV | Market Commentary: Teva trades after disappointing outlook; Volcano's planned $350 million convertible on tap
|
4/24/2012 | SP | New Issue: Morgan Stanley prices $780,000 trigger phoenix autocallables linked to Teva
|
4/18/2012 | SP | Morgan Stanley plans trigger phoenix autocallables linked to Teva
|
4/3/2012 | CVEMIG | S&P rates Teva notes A-
|
4/2/2012 | CVEMIG | Moody's rates Teva notes A3
|
3/30/2012 | EM | New Issue: Israel's Teva prices €1 billion 2 7/8% seven-year notes at 100 bps over mid-swaps
|
3/29/2012 | CVEMIG | S&P rates Teva notes A-
|
3/23/2012 | EM | Israel's Teva plans euro- and Swiss franc-denominated senior notes
|
3/23/2012 | EM | Market Commentary: Emerging markets quiet; funds see $851 million of inflows; China Development prices add-on
|
2/15/2012 | CV | Market Commentary: Teva trades in line after earnings; NetApp heavy ahead of earnings; Central European gains
|
12/21/2011 | CVEMIG | Teva to end 2011 with $14.5 billion of debt, expects decrease in 2012
|
12/21/2011 | CVEMIG | Moody's: Teva unchanged
|
12/9/2011 | CVEMIG | Teva files automatic shelf registration for ADS, debt, units, warrants
|
12/6/2011 | BKCVEMIG | Teva has 'robust' rating, 'significant' cash flow for deleveraging
|
12/5/2011 | CV | Market Commentary: Convertibles quiet as equities react to European debt news; BorgWarner adds; AMR slips
|
11/8/2011 | EMIG | New Issue: Teva Pharmaceutical sells $5 billion of senior notes in six tranches
|
11/8/2011 | IG | Market Commentary: International Paper brings $1.5 billion; Halliburton sells $1 billion; HP firms; Hershey flat
|
11/7/2011 | EMIG | Israel's Teva Pharmaceutical to sell $4 billion of senior notes
|
11/7/2011 | IG | Market Commentary: Canadian Railway, Zimmer bring deals; Jefferies bucks sector weakness; telecom bonds widen
|
11/7/2011 | BK | Teva to repay $3.75 billion short-term debt used for Cephalon purchase
|
11/7/2011 | CV | Market Commentary: Jefferies adds after unwinding euro debt; Amgen unmoved on share buyback, debt deal
|
11/7/2011 | CVEMIG | S&P assigns Teva notes A-
|
11/2/2011 | BK | Teva borrows approximately $8.5 billion during third-quarter 2011
|
10/14/2011 | CV | Cephalon's 2.5%, 2% notes convertible into cash following Teva merger
|
8/22/2011 | CV | Cephalon announces expected make-whole conversion amounts for notes
|
8/9/2011 | CV | Teva Pharmaceutical unit's 0.25% debentures convertible until Nov. 11
|
8/2/2011 | CVEMIG | Moody's: Teva unchanged
|
5/31/2011 | CV | Market Commentary: Forestar to price $100 million deal; Newmont steady to down; Host little moved on partial call
|
5/31/2011 | CVLM | Teva will no longer redeem series A and B convertibles on June 21
|
5/23/2011 | CVLM | Teva to redeem 0.25%, 0.5% notes; holders may convert until June 17
|
5/11/2011 | CV | Teva Pharmaceutical unit's 0.25% debentures convertible until Aug. 12
|
5/3/2011 | BKCACVHY | Moody's confirms Valeant
|
5/2/2011 | CV | Market Commentary: Cephalon adds outright, flat on hedge after Teva bid; Teva adds too; International Coal up
|
5/2/2011 | CVEMIG | S&P affirms Teva
|
5/2/2011 | CVEMIG | Moody's affirms Teva
|
5/2/2011 | CVEMIG | Teva plans to use cash, bonds to acquire Cephalon for $6.8 billion
|
3/16/2011 | CVEMIG | S&P rates Teva notes A-
|
3/16/2011 | CVEMIG | Moody's rates Teva notes A3
|
3/16/2011 | EMIG | New Issue: Teva Pharmaceuticals prices $750 million of senior notes in two tranches
|
3/16/2011 | IG | Market Commentary: Cliffs Natural sells $1 billion, Teva and AGL Capital price deals; Bank of America widens
|
2/4/2011 | CV | Outright convertible players add 1.9% for January, Citigroup says
|
2/1/2011 | CV | Teva Pharma's 0.25%, 0.5% debentures convertible until May 13
|
1/24/2011 | CV | Market Commentary: Salesforce.com under pressure; RadioShack lower; Molycorp plans mandatory; Nielsen on tap
|
1/13/2011 | CV | Market Commentary: Dendreon to price $500 million convertibles; Allergan active amid possible short covering
|
1/12/2011 | CV | Market Commentary: Hedged holders lose on Teva call; Nielsen mandatory to price Jan. 24 week; GM mandatory up
|
1/12/2011 | CV | Teva cuts conversion price of 1.75% convertibles due 2026
|
1/11/2011 | CVLM | Teva to redeem $813 million 1.75% convertible debentures due 2026
|
11/10/2010 | CV | Teva cuts conversion prices on 0.5%, 0.25% convertibles due 2024
|
11/9/2010 | CV | Teva 0.25%, 0.5% notes convertible into ADRs from Nov. 11 to Feb. 14
|
8/10/2010 | CV | Teva says 0.5%, 0.25% notes convertible till Nov. 11, adjusts conversion price on two other series
|
6/22/2010 | CV | Market Commentary: Teva series Ds active in trade; Transocean ends lower; Biovail, Lincare better; PPL adds
|
6/15/2010 | EMIG | New Issue: Teva Pharmaceutical prices $2.5 billion of senior notes in three tranches
|
6/15/2010 | IG | Market Commentary: Teva, Lincoln National, Pall price deals; BP keeps widening; new deals strong in trading
|
6/2/2010 | CV | Teva Pharmaceutical holders may convert 0.5%, 0.25% notes 'til Aug. 12
|
6/1/2010 | CV | Market Commentary: Transocean extends fall; Superior Energy off; Western Refining under pressure; Teva slips
|
5/21/2010 | SP | New Issue: Barclays prices $1 million 8% reverse convertibles linked to Teva Pharmaceutical
|
3/19/2010 | CVEMIG | S&P ups Teva Pharmaceutical
|
3/18/2010 | BKBWCV | Teva to use cash, lines of credit to fund Ratiopharm acquisition
|
3/18/2010 | CVEMIG | Moody's affirms Teva Pharmaceuticals
|
3/10/2010 | SP | New Issue: Barclays prices $31.5 million 10% income enhanced reverse exchangeables linked to Teva
|
2/18/2010 | CV | Teva Pharmaceutical holders may convert 0.5%, 0.25% notes up to May 13
|
1/13/2010 | CVEMIG | Moody's lifts Teva
|
11/11/2009 | CV | Teva Pharmaceutical's 0.5% debentures now convertible up to Feb. 16
|
11/3/2009 | CV | Teva extends convertibility of 0.5% notes, 0.25% notes until Feb. 16
|
10/14/2009 | CVEMIG | Moody's upgrades Teva
|
9/14/2009 | SS | Teva Pharmaceuticals eyes emerging markets as part of growth strategy
|
8/5/2009 | CV | Teva adjusts conversion prices of 0.25%, 1.75% convertibles, announces convertibility of 0.5% bonds
|
8/3/2009 | CV | Teva extends convertibility of 0.25% convertibles to Nov. 11
|
7/30/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
7/27/2009 | CV | Teva extends convertibility of 0.25% convertibles to Thursday
|
7/23/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
7/22/2009 | CV | Teva extends convertibility of 0.25% convertibles to Monday
|
7/21/2009 | CV | Teva extends convertibility of 0.25% convertibles to Friday
|
7/20/2009 | CV | Teva extends convertibility of 0.25% convertibles to Thursday
|
7/16/2009 | CV | Teva extends convertibility of 0.25% convertibles to Tuesday
|
7/15/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Monday
|
7/13/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Thursday
|
7/9/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
7/8/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Monday
|
7/2/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
6/29/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Thursday
|
6/25/2009 | IG | Market Commentary: Citigroup, Jefferies, Analog Devices, MassMutual, Torchmark sell notes; Merck busy, up again
|
6/24/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Tuesday
|
6/23/2009 | CV | Teva extends convertibility of 0.5%, 0.25% convertibles to Friday
|
6/22/2009 | CV | Teva issues notices of convertibility for 0.5%, 0.25% convertibles
|
6/18/2009 | CV | Market Commentary: Whiting Petroleum slips below par on debut; Watson up; newly priced issues in focus
|
6/18/2009 | CV | Teva series A, series B debentures convertible through June 23
|
5/18/2009 | CVEM | Moody's lifts Teva Pharmaceuticals outlook to positive
|
4/7/2009 | SS | Market Commentary: Spread widens on Wyeth stock; Biogen jumps on buyout talk; Cubist makes difficult takeover target
|
3/30/2009 | CV | Teva A convertibles best for high delta; Cs offer more balance, Barclays analysts say
|
1/6/2009 | CVEMIG | Moody's affirms Teva, ups Barr loan
|
12/23/2008 | SS | Barr ceases trading following acquisition by Teva
|
12/19/2008 | SS | Teva, Barr merger on track to close Tuesday following latest approvals
|
12/4/2008 | CVEMIG | Teva files automatic shelf registration
|
11/25/2008 | SS | Watson Pharmaceuticals to acquire generic products following merger of Teva, Barr
|
11/21/2008 | SS | Barr Pharmaceuticals shareholders say 'yes' to deal with Teva
|
11/18/2008 | CV | Market Commentary: Financials mostly weaker; Medtronic, Teva mixed; Digital River strong despite steep slide in shares
|
10/28/2008 | SS | Market Commentary: Banks try to bail on Huntsman-Hexion; Teva keeps financing facilities; banks still stingy with credit
|
10/27/2008 | BKSS | Barr Pharmaceuticals amends credit facilities ahead of merger with Teva
|
9/3/2008 | SS | Teva, Barr respond to second request from FTC
|
8/28/2008 | CV | Market Commentary: Teva edges higher amid outright interest; Peabody eases; Fleetwood aims to extend 5% convertibles
|
7/22/2008 | SS | Bentley shareholders OK merger agreement with Teva; acquisition complete
|
7/18/2008 | SS | Market Commentary: Yahoo!-Microsoft saga takes another turn as Legg Mason backs Yahoo! board
|
7/18/2008 | BKCVEMIG | Moody's may upgrade Barr, affirms Teva
|
7/18/2008 | CV | Market Commentary: Bank of America, Washington Mutual, Wachovia gain; Teva climbs; Sino-Forest, Trina quiet on debuts
|
7/18/2008 | EMIG | Teva acquires Barr, plans tapping of long-term debt market
|
7/18/2008 | IG | Market Commentary: Week of nearly $4 billion ends on quiet note; Freddie Mac announces future issue
|
7/18/2008 | SS | Teva to acquire Barr for $7.46 billion and $1.5 billion in debt
|
7/8/2008 | CV | Market Commentary: EMC trades mixed, Teva up outright; Lehman mostly higher; Transocean adds despite lower oil prices
|
7/3/2008 | SS | Bentley, Teva lower per-share cash purchase price in merger
|
7/1/2008 | SS | Bentley Pharmaceuticals' spinoff of CPEX clears way for merger with Teva
|
3/31/2008 | SS | Market Commentary: Airlines mull further talks; CME opposes regulation plan; MI Development considers shake-up
|
3/31/2008 | SS | Teva to expand in Spain with acquisition of Bentley Pharmaceuticals
|
3/17/2008 | CV | S&P boosts Teva
|
3/13/2008 | CV | Lehman analysts: Teva tranche D convertibles now look better to buy
|
2/29/2008 | CV | Market Commentary: EMC, Mylan, Sprint, National Retail convertibles all lower; Teva flat; equities sink
|
2/28/2008 | CV | Market Commentary: Convertibles mostly lower; National Retail edges below par; Thornburg, Nextel drop
|
2/27/2008 | CV | Lehman analysts: Sell the A, C Teva convertibles to buy the Teva Bs
|
2/27/2008 | CV | Market Commentary: Convertibles trade mixed; Teva, Fannie Mae active; National Retail prices upsized notes
|
1/31/2008 | CV | S&P could lift Teva
|
10/16/2007 | CV | Teva calls $36 million of 0.375% convertible debentures due 2022
|
10/16/2007 | SP | Market Commentary: Svensk, Lehman bring large exchangeable deals; Deutsche plans $250 million Morningstar offering
|
10/15/2007 | CVSP | New Issue: Svensk prices $73.7 million 10% exchange notes linked to Teva Pharmaceuticals
|
10/11/2007 | SP | Svensk to price fixed-rate exchange notes linked to Teva Pharmaceuticals
|
5/14/2007 | SS | Market Commentary: DaimlerChrysler up; Magna off; Ford flies; Cleveland-Cliffs up; Mosaic higher; Teva advances
|
2/14/2007 | CV | Market Commentary: Genzyme, Transocean climb on results; Teva gains further on outlook; Archer Daniels Midland plans deal
|
12/22/2006 | SP | New Issue: Barclays sells $2 million 8% reverse convertibles linked to Teva
|
12/6/2006 | SP | Barclays to price 8% reverse convertibles linked to Teva
|
12/4/2006 | SP | Barclays to price 8% reverse convertibles linked to Teva Pharmaceutical
|
11/7/2006 | BT | Teva's third-quarter 2006 net sales up 74%, cash hits $2.1 billion
|
11/7/2006 | BTCVEM | Teva board OKs repurchase of up to $600 million convertibles, shares
|
10/6/2006 | BT | Market Commentary: Acorda up 10% as Elan, Biogen ease on Tysabri news; Panacos up on takeover; Memory up on PIPE
|
9/26/2006 | BT | Teva, Protalix to collaborate on two proteins
|
9/20/2006 | BT | Teva, Procognia sign agreement for biopharmaceuticals development
|
9/5/2006 | BT | Teva, Active Biotech phase 2b study of laquinimod meets primary endpoint, triggers milestone
|
8/29/2006 | BT | Market Commentary: Teva lower; Endo, Penwest up; StemCells gains 7%; Nastech higher; Hemispherx rises 11%
|
8/29/2006 | BT | Teva settles OxyContin litigation with Purdue Pharma
|
8/23/2006 | BT | Teva ends production at Cidra plant as part of global rationalization strategy
|
8/23/2006 | BT | Market Commentary: Cell Therapeutics' stock takes off on positive phase 1 data; Cubist's stock up again on Theravance news
|
8/21/2006 | BT | Market Commentary: Dynavax says flu vaccine effective on divergent viral strains; Inverness to wrap $151.25 million PIPE
|
8/21/2006 | BT | Teva says Health Canada approves Azilect for Parkinson's disease
|
8/14/2006 | BT | Teva launches generic Zoloft
|
8/8/2006 | BT | Teva reports second-quarter net income up 124%, net sales rose 77%
|
8/8/2006 | CV | Market Commentary: McData gains with offer; Teva rides earnings boost; Scottish Re firms as put stays; Charter slips on loss
|
8/8/2006 | BT | Market Commentary: Barrier loses 13%; Teva up more than 5%; Antigenics comes off highs; Amylin falls 7%
|
8/4/2006 | BT | Teva announces final approval of Venlafaxine HCl tablets
|
7/27/2006 | BT | Teva to test glatiramer acetate in phase 3 trial
|
7/26/2006 | CV | New Issue: Barclays sells $3 million 9% reverse convertibles linked to Teva Pharmaceutical
|
7/20/2006 | BT | Mylan, Glenmark, Cadila, Teva to sell generic Mobic for osteoarthritis
|
7/18/2006 | BT | Antares, Teva sign license agreement for disposable injection device
|
7/17/2006 | CV | Market Commentary: Nabors falls with oil prices; Electronics for Imaging brightens with upgrade; Lucent still weak on forecasts
|
7/14/2006 | BT | Market Commentary: deCODE secures $30 million from stock sale; Micrus stock edges up following public stock offering
|
7/14/2006 | CV | Market Commentary: Ford slides as story sputters; GM weaker; deCODE Genetics widens; Teva steady despite loss to Forest
|
7/13/2006 | BT | Forest wins over generic on Lexapro patent
|
7/12/2006 | BT | Eisai, Teva end collaboration agreement for rasagiline
|
7/12/2006 | BT | Teva: FDA tentatively approves its generic form of Novartis' Lotrel for hypertension
|
7/10/2006 | CV | Barclays plans issue of 9% exchangeables linked to Teva Pharmaceutical
|
6/30/2006 | BT | Teva receives FDA approval for generic Zoloft tablets
|
6/27/2006 | BT | Teva launches generic Biaxin, then puts sales on hold
|
6/23/2006 | BT | Teva: Novartis' Sandoz unit seeks to delay first FDA approval of generic Zocor
|
6/23/2006 | BT | Teva to sell generic Zocor; Dr. Reddy's to sell generic Proscar, Zocor
|
6/21/2006 | CV | Market Commentary: Teva sinks outright, holds up dollar neutral; Group 1 re-offered; $2 billion new deals seen pricing Thursday
|
6/20/2006 | BT | Teva: study shows Copaxone reduces relapse rate in patients with multiple sclerosis
|
6/19/2006 | BT | Teva gets approval for generic Proscar tablets
|
6/14/2006 | BT | Teva gains tentative approval for generic versions of Merck's Hyzaar
|
5/31/2006 | BT | Teva: Copaxone reduced relapses, stabilized disability when Avonex failed
|
5/30/2006 | BT | Teva announces tentative approval for generic Cozaar tablets
|
5/25/2006 | CV | Market Commentary: Encysive gains outright on FDA submission; Omnicare, XM Satellite better on hedge amid stock declines
|
5/22/2006 | BT | Teva given approval for generic Lexapro
|
5/17/2006 | BT | Teva receives FDA approval for Azilect for Parkinson's
|
5/10/2006 | BT | Teva reports net sales up 28% to $1.672 billion
|
5/10/2006 | CV | Market Commentary: SanDisk, Broadwing climb on debuts; Amkor, JDS Uniphase, Manor Care plan deals; Teva steady on loss
|
5/8/2006 | BT | Teva gets aNDA approval for polyethylene glycol product
|
5/5/2006 | BT | Teva says first-quarter sales of Copaxone for multiple sclerosis up 29% to $329 million
|
5/5/2006 | CV | Market Commentary: Safenet gains on earnings, stock buyback; Scottish Re widens after poor quarter; Finisar flat after rally
|
5/5/2006 | BT | Market Commentary: Northstar Neuroscience stock climbs on upsized IPO; Praecis stock jumps 22.3% on earnings
|
5/1/2006 | BT | Teva says court finds FDA denial of exclusivity period for IVAX's generic Zocor unlawful
|
5/1/2006 | BT | Market Commentary: Teva shares, convertibles gain on Zocor ruling; NeoPharm off amid downsizing; Alnylam, Idenix drop
|
5/1/2006 | CV | Market Commentary: Level 3 gains on $1.2 billion acquisition; Teva gets court boost; Human Genome tightens on drug trials
|
4/25/2006 | BT | FDA approves Teva's generic Pravachol
|
4/21/2006 | BT | Teva receives tentative FDA approval for generic Protonix, court actions continue
|
4/20/2006 | BT | Teva says court lifts stay of approval against generic Pravachol, Apotex files appeal
|
4/19/2006 | BT | Teva closer to launching generic Pravachol after court rejects Apotex injunction
|
4/12/2006 | BT | Teva: FDA denies Apotex's request for pravastatin exclusivity
|
4/12/2006 | BT | Teva to ship FDA-approved Mitoxantrone Hydrochloride Injection USP
|
4/5/2006 | BT | Teva says higher dose of Copaxone increases benefit in MS patients
|
4/3/2006 | BT | FDA approves Teva's generic injection for iron intoxication
|
3/16/2006 | BT | Teva expects to gain exclusivity for cholesterol drug pravastatin in April
|
3/6/2006 | BT | FDA grants tentative approval to Teva's Topiramate Tablets, 50 mg
|
3/6/2006 | CV | Market Commentary: Coherent, Albany International launch new deals; Teva, General Motors gain on positive news
|
3/3/2006 | BT | Shire sues Teva for patent infringement after Teva files for approval of generic Adderall
|
2/28/2006 | BT | Market Commentary: Generex recoils along with most flu names; King Pharma clubbed; Elan, Biogen hit by analyst poll
|
2/27/2006 | BT | Teva announces tentative FDA approval of Ondansetron Injection USP
|
2/24/2006 | BTCV | Teva over-allotment option partially exercised, raising convertibles to $1.3925 billion
|
2/16/2006 | BT | Teva gets tentative approval for Aciphex generic
|
2/13/2006 | BT | Teva announces tentative FDA approval of Adenosine injection
|
2/9/2006 | BT | Teva calls Pfizer patent violation allegations 'baseless'
|
2/8/2006 | BT | Pfizer asks FDA to recall Teva, Sandoz generic azithromycin
|
2/2/2006 | BT | Market Commentary: Valera debut shares gain 10%; Theravance up; ImClone sinks; Nabi rockets; Teva pressured
|
2/2/2006 | CV | Market Commentary: ImClone steady despite lack of Bristol-Myers interest; Teva under pressure; Omnicare edges lower
|
1/30/2006 | BT | Teva receives FDA OK for generic Desmopressin Acetate Tablet
|
1/30/2006 | BT | Teva says Q4 sales of Copaxone increased 24%
|
1/27/2006 | BT | Market Commentary: Arena up after follow-on; Altus interest grows; Nektar, Pfizer up; Glaxo gains on Gates' TB pledge; Teva prices
|
1/27/2006 | BTCVEM | Moody's rates Teva Pharmaceutical notes, convertibles Baa2
|
1/27/2006 | CV | Market Commentary: Deals from Teva, AAR draw attention to new issues; Nektar in play on product rumors; GM up
|
1/27/2006 | BTEM | New Issue: Israel's Teva Pharmaceutical sells $1.5 billion in 2016 and 2036 notes
|
1/27/2006 | BTCVEM | New Issue: Teva prices $1.25 billion convertibles at 1.75%, up 25%, 0.25%, up 15%
|
1/27/2006 | BT | Court ruling allows Barr, Teva to market generic allergy medication
|
1/26/2006 | BT | Market Commentary: Altus rockets out of gate; Teva talk tightened; Alexion zooms; Amylin better; Cephalon gains; Nektar rises
|
1/26/2006 | BTCVEM | S&P assigns Teva Pharmaceutical notes BBB
|
1/26/2006 | CV | Market Commentary: New issues mixed, NRG trades up, UAG flat; Juniper drops; DRS launches $300 million of convertibles
|
1/26/2006 | BTEM | Price talk emerges on Teva $1.5 billion two-tranche straight debt, $1.25 billion of convertibles
|
1/25/2006 | BT | IVAX shareholders mostly choose stock in Teva merger
|
1/25/2006 | BT | Market Commentary: Teva launches $2.75 billion bonds; NitroMed pockets $52.6 million; SGX Pharma sweetens IPO talk
|
1/25/2006 | CV | Market Commentary: Cracker Barrel, Calpine gain; Charter edges lower; Teva, AAR launch convertible deals
|
1/25/2006 | CV | Teva Pharmaceuticals to price $1.25 billion 20-year convertibles in two tranches
|
1/25/2006 | BTEM | Teva launches $2.75 billion of bonds to repay bridge financing for Ivax merger
|
1/23/2006 | BT | U.S. agency clears Teva, IVAX merger after companies agree to divest 11 generics, distribution rights
|
1/13/2006 | BT | Wyeth, Teva patent settlement over Effexor XR now in effect
|
1/12/2006 | BT | Teva announces tentative FDA approval of generic version of Depakote
|
1/4/2006 | CV | Market Commentary: Convertible market sees broad-based gains, GM, Ford lift; airlines better, Calpine adds points
|
1/3/2006 | BT | Teva gets preliminary FDA approval for Simvastatin anti-cholesterol tablets
|
1/3/2006 | BTCV | Teva does not exercise fundamental change option for IVAX 1.5% convertibles due 2025
|
12/22/2005 | BT | Par to buy eight generics from Teva, Ivax
|
12/20/2005 | BTCVEM | Teva files shelf, may use sales to finance IVAX acquisition
|
12/19/2005 | BT | Market Commentary: Pfizer, other Big Pharmas zoom; generic names Barr, Teva plunge; Cubist, Rigel, Xoma, Lexicon off
|
12/9/2005 | BT | Cephalon settles patent infringement suit with Teva
|
12/9/2005 | BT | Market Commentary: Adams slides after secondary; Voyager IPO delayed; Cephalon spikes, Teva rises; Genitope up
|
12/9/2005 | BT | Teva's generic antibiotic Cefprozil approved by FDA
|
12/9/2005 | CV | Market Commentary: Cephalon, Teva gain on patent settlement; eyes turn toward Omnicare; Alltel mostly quiet
|
12/8/2005 | CV | Market Commentary: New SafeNet convertibles gain with shares; technology and biotech firmer; LabCorp gains
|
12/7/2005 | BT | Teva receives final approval for generic OxyContin
|
12/6/2005 | BTCV | Teva does not expect to choose fundamental change option for IVAX 1.5% convertibles due 2025
|
12/5/2005 | BT | Par, Three Rivers and Teva say FDA approved ribavirin, generic of Roche's Copegus to treat hepatitis C
|
12/1/2005 | BT | Teva starts trial of Agilect for Parkinson's disease
|
11/30/2005 | BT | Teva gets ANDA approval for Zaleplon to treat insomnia; patent lawsuit involving Sonata generic still pending
|
11/29/2005 | BT | Antares signs deal with Teva unit for injection devices; unit buys 400,000 shares of Antares common stock
|
11/28/2005 | CV | Market Commentary: Airline, retail convertibles attract bids; Platinum Underwriters launches $150 million preferreds
|
11/28/2005 | BTEM | Teva Pharmaceuticals draws down $350 million U.S. loan
|
11/22/2005 | BT | Market Commentary: Pain Therapeutics falls on poor trial data; Sinovac off of profit taking; Point Therapeutics rises
|
11/15/2005 | BT | Teva: Research shows Copaxone may induce neuronal metabolic recovery in multiple sclerosis patients
|
11/14/2005 | EM | S&P affirms Teva Pharmaceutical
|
11/14/2005 | BT | Teva receives approval for Azithromycin tablets
|
11/11/2005 | BT | S&P affirms Teva Pharmaceutical
|
11/11/2005 | CV | S&P affirms Teva Pharmaceutical
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
11/2/2005 | BTCVEM | Moody's gives Teva Baa2 issuer rating
|
10/31/2005 | BT | Teva receives approval for Glipizide, Metformin
|
10/25/2005 | CV | Market Commentary: Sovereign slides, Schlumberger, Sepracor lift; Essex reoffered at 98; Flextronics drops after close
|
10/21/2005 | BT | Court ruling favors Teva on generic Pravachol exclusivity
|
10/18/2005 | BT | Teva and Wyeth settle Effexor XR litigation
|
10/14/2005 | BT | Teva receives favorable ruling from Japanese Patent Office on pravastatin
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
9/6/2005 | BT | Market Commentary: Chiron rises on rejection of bid from Novartis; Barr, Teva gain; New River higher; Andrx falls
|
8/3/2005 | CV | Market Commentary: Human Genome to price $230 million of convertibles; Reebok paper jumps on buyout news
|
8/1/2005 | CV | Market Commentary: CommScope jumps, but Isolagen tumbles amid slightly weaker convertibles market
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|
7/25/2005 | CV | Market Commentary: CSK on tap; L-3, Barnes, Manor Care, FTI, Conseco later in week; Ivax in quandary on Teva merger
|
7/25/2005 | BT | Market Commentary: Teva purchases Ivax, both higher; Endo Pharma climbs on possible sale of Ivax pain drug
|
7/25/2005 | BTCVEM | S&P puts Teva on negative watch
|
7/19/2005 | BT | Market Commentary: Able bankruptcy sparks buying by restructuring specialists; Amgen a blowout; Genentech weighs on QLT
|
7/19/2005 | BT | S&P: U.S. generic drug industry entering more challenging period; Alpharma, Mylan, Teva, Watson at risk
|
5/25/2005 | CV | S&P ups Teva view to stable
|
4/15/2005 | CV | Market Commentary: GM, Ford selling accelerates; El Paso, Calpine, NRG plunge; Ivax, Teva lose; Lucent, Tyco unwound
|
2/28/2005 | CV | Market Commentary: Elan hurt, Biogen stable; Teva up, Schering slips; King trips; Yellow skids; Manpower lower; Saks off
|
2/22/2005 | CV | Market Commentary: Level 3 converts rise on private deal; UniSource, Allied Waste deals emerge; Par, Ivax, Teva up
|
12/22/2004 | CV | New Issue: Lehman prices $5 million 0% up 13.85% notes linked to Teva
|
12/21/2004 | CV | Teva ups buyback program to $600 million
|
10/15/2004 | CV | Top volatility plays: BankUnited, Schlumberger, Teva, HCC Insurance, Quanex, Merrill says
|
10/11/2004 | CV | Market Commentary: Northwest, Delta lead lower on fuel prices, pilot contract concerns; drug paper higher
|
9/3/2004 | CV | Teva board authorizes buybacks of $300 million of shares, convertibles
|
8/30/2004 | CV | Market Commentary: LNR convertible leveled by $1.9 billion cash takeover; United Rentals falls on SEC inquiry
|
8/20/2004 | CV | Teva Pharmaceutical says almost all $349 million of 0.75% debentures converted
|
8/17/2004 | CV | S&P: Teva unaffected
|
7/30/2004 | CV | Teva calls all $349 million of 0.75% convertibles
|
5/20/2004 | CV | Market Commentary: Airline paper cheapens further, despite rise in stocks; Guilford shelf uplifts holders of rich bonds
|
2/6/2004 | CV | Teva greenshoe partially exercised, raising convertibles to $1.094 billion
|
2/3/2004 | CV | Market Commentary: First Data's call catches some off guard, Delta reoffered at 97, descends to 95.75 bid; Tyco up
|
1/29/2004 | CV | Market Commentary: Wyeth, Sallie Mae, Lockheed floaters see demand; hedgies hurt by premium contractions
|
1/23/2004 | CV | S&P rates new Teva convertibles BBB
|
1/23/2004 | CV | Market Commentary: Comtech dips on telecom slump; other new issues still on the rise; buyer seen for Adelphia converts
|
1/23/2004 | CV | Lehman analysts add new Teva 0.5% convert to recommended portfolio, overweight on stock
|
1/22/2004 | CV | Market Commentary: Komag delayed a day on Maxtor earnings, still bid up 2.5 points; Kodak's paper snapped up on new plan
|
1/22/2004 | CV | New Issue: Teva sells $1 billion convertibles; Tranche A at 0.5%, up 29%; Tranche B at 0.25%, up 20%
|
1/21/2004 | CV | Teva $1 billion overnight two-tranche convert talked at 0.25-0.5%, up 29-35% and 0.0-0.25%, up 20-26%
|
1/21/2004 | CV | Market Commentary: Deals totaling $1.9 billion at bat; Citi/News, Teva see only offers; Komag tightened, still bid higher
|
10/31/2003 | CV | S&P cuts Teva outlook
|
10/15/2003 | CV | S&P ups Teva to BBB
|
10/15/2003 | CV | Teva says almost all 1.5% convertibles exchanged for stock
|
10/2/2003 | CV | Market Commentary: Providian gains sharply amidst big volume on talk about Wells Fargo takeover; buyers aplenty
|
9/29/2003 | CV | S&P puts Teva on positive watch
|
9/25/2003 | CV | Teva calls 1.5% convertibles
|
9/25/2003 | CV | Market Commentary: Pharma Resources gains to 104 despite complaint; Bristol-Myers jumbo seen offered at par in gray
|
8/28/2003 | CV | Market Commentary: Miscellaneous scraps of convertible paper trading; action to heat up next week
|
6/24/2003 | CV | Moody's rates Halliburton convertible Baa2
|
6/23/2003 | CV | Market Commentary: Market cheapening poses double-edged sword as new paper suffers; 4 deals emerge
|
5/5/2003 | CV | Market Commentary: Tech names higher, partly on Lucent/Juniper agreement; LIN, Edwards pricing before Tuesday open
|
4/30/2003 | CV | Market Commentary: Tyco convertibles drop to 97 on accounting charge news only to end higher at 102
|
4/3/2003 | CV | Market Commentary: Refinancing hopes, quest for delta provide buying catalyst; HealthSouth firmer on rescue hopes
|
3/5/2003 | CV | Market Commentary: Watson trades up out of gate, Provident plunges, call scare ripples throughout market
|
3/4/2003 | CV | Deutsche says Teva 0.375% convertibles best for outrights, 1.5% least attractive
|
1/14/2003 | CV | Market Commentary: Some expect credit spread rally to begin leveling off; Oneok mandatory guidance emerges
|
11/27/2002 | CV | Market Commentary: Opportunists take profits in Skyworks, new issues gain
|
11/19/2002 | CV | Market Commentary: New issue terms, credits not so fantastic, but illustrate appetite
|
11/18/2002 | CV | Market Commentary: Trickle of new issues providing hope for eager buyers
|
11/15/2002 | CV | Market Commentary: American Tower gains sharply on hopes of exchange offer; 3M, Teva continue northward
|
11/15/2002 | HY | American Tower gains sharply on hopes of exchange offer; 3M, Teva continue northward
|
11/14/2002 | CV | Market Commentary: Buyers emerge from sidelines to bid up high delta, gamma issues
|
11/13/2002 | CV | S&P rates Teva at BBB-
|
11/13/2002 | CV | Market Commentary: Teva deal gets warm welcome in an otherwise tepid market
|
11/13/2002 | CV | New Issue: Teva $375 million convertibles yield 0.375%, up 18%
|
11/12/2002 | CV | Market Commentary: New deals provide stimulation late, after very quiet session
|
11/12/2002 | CV | Teva launches quick-sale $375 million converts at 0.375-0.625%, up 18-22%
|
4/10/2002 | CV | Deutsche analysts say credit work provides insight for generic drug picks
|
1/7/2002 | CV | Market Commentary: Convertibles sink on profit taking as stocks retreat
|